Novartis needs to make Gilenya cheaper for MS, or find generous payers
This article was originally published in Scrip
Novartis may struggle to convince payers that Gilenya (fingolimod), its oral treatment for relapsing remitting multiple sclerosis (RRMS), is more cost effective than beta interferon, unless the cost of the drug falls below $3476 per month or a higher than normal willingness to pay (WTP) threshold is accepted by payers. This is the main conclusion of a study conducted by researchers at the University of Connecticut School of Pharmacy and the Hartford Hospital and published in the current issue of the Journal of Medical Economics (J Med Econ 2012; 1–9).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.